Research Progress in the Treatment of Septic Shock with Levosimendan

YU Xing-feng

PDF(1565 KB)
KANGGANRAN YAOXUE ›› 2024, Vol. 21 ›› Issue (6) : 555-558. DOI: 10.13493/j.issn.1672-7878.2024.06-001

Research Progress in the Treatment of Septic Shock with Levosimendan

  • YU Xing-feng*
Author information +
History +

Abstract

Septic shock occurs when pathogenic microorganisms and their toxins invading the blood circulation activate the host's cellular and humoral immune systems, producing various cytokines and inflammatory mediators to cause systemic inflammatory response syndrome, and further act on various organs and systems, causing histiocytic destruction, metabolic disorders, dysfunction, and even multiple organ dysfunction, ultimately leading to a critical syndrome with shock as a prominent manifestation. Levosimendan, as a calcium ion sensitizer, can not only improve myocardial contractility without increasing cellular oxygen consumption, but also dilate coronary arteries and systemic blood vessels, thereby improving hemodynamics. In this article, the epidemiological characteristics and pathogenesis of septic shock, the pharmacological effects and mechanisms of levosimendan, and the application and potential risks of levosimendan in septic shock are mainly reviewed, to provide a reference for the clinical use of levosimendan.

Key words

levosimendan / septic shock / clinical treatment / research progress

Cite this article

Download Citations
YU Xing-feng. Research Progress in the Treatment of Septic Shock with Levosimendan. KANGGANRAN YAOXUE. 2024, 21(6): 555-558 https://doi.org/10.13493/j.issn.1672-7878.2024.06-001

References

[1] 陈蓉,柳小霞,许伟伟. 重症超声指导下液体复苏联合针对性护理在脓毒性休克患者中的应用效果分析[J]. 中国社区医师,2023,39(5):130-132.
[2] 问军锋,马岚. 左西孟旦治疗脓毒性休克患者临床效果观察及对血流动力学水平的影响[J]. 河北医药,2017,39(10):1468-1470.
[3] 陈崇高,符厚萱. 基于心脏功能、血流动力学指标评价左西孟旦治疗脓毒症休克的有效性[J]. 现代医学与健康研究电子杂志,2023,7(11):13-15.
[4] 董磊,张辉,段美丽,等. 脓毒性休克的临床流行病学调查——1087 例全国多中心临床研究[J]. 中国临床医学,2010,17(3):436-438.
[5] 杨晓静,马琴琴,张洪艳,等. 目标导向治疗联合重症超声在老年脓毒性休克患者中的应用价值[J]. 河北医药,2022,44(6):891-894.
[6] 王智钧,林燕金,吴格立,等. 胸腺肽α1 对老年脓毒性休克患者预后的影响[J]. 中国现代医药杂志,2023,25(4):53-55.
[7] 欧伟良,张媛莉. 中性粒细胞胞外陷阱在脓毒症发病机制中的作用[J]. 广东医科大学学报,2023,41(3):340-343.
[8] 凌梦雨,邱逢意,许飚,等. 血必净注射液对脓毒性休克患者凝血功能障碍的 Meta 分析[J]. 中国民族民间医药,2023,32(5):105-110.
[9] 周序满. 左西孟旦辅助治疗对脓毒症休克患者血流动力学及疾病相关指标水平的影响[J]. 现代医学与健康研究电子杂志,2023,7(2):67-70.
[10] 肖琦,毕安平,邹灯秀,等. ICU 脓毒性休克并发低体温病人临床特征及危险因素分析[J]. 护理研究,2023,37(3):522-526.
[11] 余琨,陈淼,陈涛,等. 重症超声在成人脓毒性休克患者液体复苏中的临床应用价值[J]. 中国中西医结合急救杂志,2023,30(2):185-190.
[12] 陈思,吴淑华. 血必净注射液联合左西孟旦治疗脓毒性休克疗效观察[J]. 现代中西医结合杂志,2018,27(1):73-76.
[13] 韩春凤,王轩,陈志诚,等. 左西孟旦治疗老年脓毒性休克心功能不全疗效观察[J]. 青岛医药卫生,2014,46(4):261-263.
[14] 刘萍. 左西孟旦对脓毒症心肌病疗效分析[J]. 山西医药杂志,2019,48(23):2922-2924.
[15] Mangini F, Bruno E, Caramia R, et al.Effectiveness of levosimendan and role of cardiac magnetic resonance in cardiogenic shock due to COVID-19 related lymphocytic myocarditis in the course of viral sepsis[J]. Arch Clin Cases, 2023, 10(1): 32-38.
[16] Maloberti A, Sun JW, Zannoni J, et al.Endothelial dysfunction in patients with advanced heart failure treated with levosimendan periodic infusion compared with optimal medical therapy:a pilot study[J]. Life, 2022, 12(9):1322.
[17] 陆智炜,何群,蔡继明. 左西孟旦早期应用对脓毒性休克患者的心肌抑制和血流动力学影响[J]. 海峡药学,2020,32(12):135-137.
[18] Chang W, Xie JF, Xu JY, et al.Effect of levosimendan on mortality in severe sepsis and septic shock:a meta-analysis of randomised trials[J]. BMJ Open, 2018, 8(3):e019338.
[19] Sun T, Zhang N, Cui N, et al.Efficacy of levosimendan in the treatment of patients with severe septic cardiomyopathy[J]. J Cardiothorac Vasc Anesth, 2023, 37(3): 344-349.
[20] 卞晓华,刘莉,夏为,等. 左西孟旦对脓毒性休克患者肾脏功能保护作用观察[J]. 临床误诊误治,2020,33(5):48-54.
[21] 黄承照. 左西孟旦对脓毒性休克患者血流动力学及心功能的影响[J]. 实用医技杂志,2019,26(8):1042-1043.
[22] 许东平,孙晋华,曾志伟,等. 无创血流动力学监测下应用乌司他丁与左西孟旦对脓毒症休克患者预后的影响[J]. 临床合理用药,2023,16(18):43-46.
[23] 刘永平,王华亭. 分析左西孟旦治疗重症冠心病并心力衰竭对心肌酶、不良反应及炎症因子的研究[J]. 中外医疗,2022,41(32):41-44.
[24] 刘红娟,耿静,何志红,等. 左西孟旦治疗脓毒症心肌抑制的疗效及对心功能的影响[J]. 临床内科杂志,2020,37(6):447-448.
[25] 闫智杰,李静,夏芝辉,等. 左西孟旦对脓毒症诱导心肌功能障碍患者血流动力学的影响及其机制研究[J]. 当代医学,2016,22(27):3-5.
PDF(1565 KB)

1001

Accesses

0

Citation

Detail

Sections
Recommended

/